Skip to Content

Entyvio (vedolizumab) Disease Interactions

There are 4 disease interactions with Entyvio (vedolizumab):


Immunosuppressive agents (Includes Entyvio) ↔ infections

Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Serious and sometimes fatal infections have been reported in patients receiving immunosuppressive agents. Caution should be exercised when considering their use in patients with severe or chronic infections. It is recommended to interrupt therapy in patients who develop a new infection while undergoing treatment and to monitor these patients closely for any sign or symptom indicative of infection.


Immunosuppressive agents (Includes Entyvio) ↔ PML

Severe Potential Hazard, Moderate plausibility. Applies to: Immunodeficiency

Immunosuppressive agents may increase the risk of progressive multifocal leukoencephalopathy (PML). Certain agents are contraindicated in patients who have or have had PML. Patients receiving chronic immunosuppressant or immunomodulatory therapy or who have systemic medical conditions resulting in significantly compromised immune system function should not be treated with these agents. Healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Withhold therapy dosing immediately and perform an appropriate diagnostic evaluation at the first sign or symptom suggestive of PML.


Vedolizumab (Includes Entyvio) ↔ liver disease

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Elevated transaminase levels with or without elevated bilirubin have occurred in patients who received vedolizumab. Care should be exercised when using this agent in patients predisposed to liver injury. Do not use vedolizumab in patients with jaundice or other evidence of significant liver injury.


Vedolizumab (Includes Entyvio) ↔ vaccination

Moderate Potential Hazard, Moderate plausibility. Applies to: Vaccination

Prior to initiating treatment with vedolizumab, all patients should be brought up to date with all immunizations per current immunization guidelines. Patients receiving vedolizumab may receive non-live vaccines (e.g., influenza vaccine injection) and may receive live vaccines if the benefits outweigh the risks. Caution and close monitoring is recommended as there are no data on the secondary transmission of infection by live vaccines in patients receiving vedolizumab.

Entyvio (vedolizumab) drug interactions

There are 109 drug interactions with Entyvio (vedolizumab)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.